What is Arcus Biosciences's total equity?

Arcus Biosciences (RCUS) reported total equity of $524M in Q1 2026.

How has Arcus Biosciences's total equity changed year-over-year?

Arcus Biosciences's total equity decreased by 1.3% year-over-year, from $531M to $524M.

What is the long-term trend for Arcus Biosciences's total equity?

Over 5 years (2020 to 2025), Arcus Biosciences's total equity has grown at a 4.7% compound annual growth rate (CAGR), from $502M to $631M.

What does total equity mean?

Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Arcus Biosciences RCUS Total Equity

Total Equity at other companies

Bristol-Myers SquibbBMY

$20.07B+15.4%

Merck & Co.MRK

$45.88B-5.1%

Regeneron PharmaceuticalsREGN

$31.42B+6.9%

AbbVieABBV

-$6.66B-569%

IDEAYA Biosciences, Inc.IDYA

$937.27M-8.5%

IncyteINCY

$5.62B+53.3%

Other financials

Income statement

See full

Revenue$17.0M-39.3%

Operating income-$134.0M-9.8%

Net income-$128.0M-14.3%

EPS (diluted)-$1.02+10.5%

Balance sheet

See full

Cash & equivalents$201.0M+4.7%

Total debt$113.0M+88.3%

Total assets$997.0M-13.8%

Cash flow

See full

Operating cash flow-$138.0M-4.5%

CapEx--100%

Free cash flow-$138.0M-3.8%

Valuation

See full

Market cap$3.54B+226%

Enterprise value$3.46B+275%

P/S15×+7.3×

Profitability

See full

Operating margin-168.6%-52.7pp

Net margin-156.4%-47.5pp

FCF margin-207.2%—

Returns & leverage

See full

Return on equity-70%+8.4pp

Debt / equity0.2×+0.1×

Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arcus Biosciences's total equity?: Arcus Biosciences (RCUS) reported total equity of $524M in Q1 2026.
How has Arcus Biosciences's total equity changed year-over-year?: Arcus Biosciences's total equity decreased by 1.3% year-over-year, from $531M to $524M.
What is the long-term trend for Arcus Biosciences's total equity?: Over 5 years (2020 to 2025), Arcus Biosciences's total equity has grown at a 4.7% compound annual growth rate (CAGR), from $502M to $631M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.